Charles Schwab
ORKA

Charles Schwab’s Oruka Therapeutics ORKA Stock Holding History

Charles Schwab’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.2M Buy
433,405
+111,456
+35% +$7.43M 0.01% 1383
2026
Q1 		$15.8M Sell
321,949
-7,547
-2% -$262K ﹤0.01% 1872
2025
Q4 		$9.99M Buy
329,496
+82,570
+33% +$2.3M ﹤0.01% 2145
2025
Q3 		$4.75M Buy
246,926
+162,924
+194% +$2.41M ﹤0.01% 2462
2025
Q2 		$942K Buy
84,002
+68,394
+438% +$713K ﹤0.01% 2920
2025
Q1 		$160K Hold
15,608
– – ﹤0.01% 3282
2024
Q4 		$303K Buy
+15,608
New +$381K ﹤0.01% 3268
2024
Q3 		– Sell
-1,249
Closed -$57.4K – 3615
2024
Q2 		$57.4K Hold
1,249
– – ﹤0.01% 3500
2024
Q1 		$26.7K Hold
1,249
– – ﹤0.01% 3422
2023
Q4 		$25.5K Hold
1,249
– – ﹤0.01% 3466
2023
Q3 		$30.1K Hold
1,249
– – ﹤0.01% 3467
2023
Q2 		$30.4K Hold
1,249
– – ﹤0.01% 3504
2023
Q1 		$29.8K Buy
+1,249
New +$32.9K ﹤0.01% 3448

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Charles Schwab's ORKA Position: Q2 2026 in Review

Charles Schwab increased its Oruka Therapeutics (ORKA) stake by 35% in Q2 2026, buying an estimated $7.43M and bringing the position to 433,405 shares worth $41.2M. The position accounts for 0.01% of the portfolio, ranked #1383.

Charles Schwab first reported a position in ORKA in Q1 2023 and has held it in 13 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Charles Schwab held 433,405 shares of Oruka Therapeutics worth $41.2M as of Q2 2026.
  • Charles Schwab bought 111,456 Oruka Therapeutics shares in Q2 2026, an estimated $7.43M.
  • Oruka Therapeutics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1383 holding.
  • Charles Schwab first reported a position in Oruka Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.